Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Edaravone for treating amyotrophic lateral sclerosis Edaravone oral (FNP1222) Amyotrophic lateral sclerosis Neurology 2023 View  |  Download
Edaravone for amyotrophic lateral sclerosis Edaravone (IV) (Radicava; MCI-186; Radicut; Edaravone) Motor neurone disease (MND or ALS) Neurology 2018 View  |  Download
ECCS-50 (Cytori stem cell therapy) for moderate to severe hand dysfunction due to Scleroderma ECCS-50 (Adipose-derived stem and regenerative cells (ADRCs)) Hand dysfunction Dermatology , Musculoskeletal System 2017 View  |  Download
Duvelisib for treating relapsed and/or refractory peripheral T-cell lymphoma Duvelisib (ABBV-954; INK-1197; IPI-145; Copiktra) Peripheral T-cell lymphoma (PTCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Duvelisib for Relapsed or Refractory Chronic Lymphocytic Leukaemia Duvelisib (ABBV-954; INK-1197; IPI-145; Copiktra) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2021 View  |  Download
Dusquetide for chemoradiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck Dusquetide (SGX942) Chemoradiation-induced oral mucositis Dental and Oral Health , Head and Neck Cancer , Toxicology 2020 View  |  Download
Durvalumab with tremelimumab for limited stage small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2019 View  |  Download
1 2 79 80 81 82 83 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications